Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | FOS | P01100 | 1/20 | 0.57 |
| ▸ | TTR | P02766 | 1/20 | 0.57 |
| ▸ | JUN | P05412 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.57 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10068659 | 0.86 | TRPV1 (0.57) | TSHRLMNAGAACYP3A4NFKB1 | |
| SCHEMBL5833247 | 0.85 | TAAR1 (0.62) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL11969383 | 0.85 | TAAR1 (0.62) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL7739503 | 0.84 | TAAR1 (0.61) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL4612057 | 0.84 | TAAR1 (0.61) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL6313682 | 0.82 | TAAR1 (0.64) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL7768865 | 0.82 | FOS (0.62) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL13219152 | 0.82 | PTPN1 (0.60) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL9885364 | 0.82 | FOS (0.62) | TAAR1TSHRMAPK1FOSTTR | |
| SCHEMBL11856806 | 0.81 | TAAR1 (0.57) | TAAR1TSHRMAPK1FOSTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9492409-B2 | Compositions and methods for the treatment of local pain | CELLIX BIO PRIVATE LIMITED (IN) | 2016-11-15 | — | — | US | disclosed |
| US-20150119423-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
| US-7034058-B2 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CORPORATION (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | KUREHA CHEMICAL INDUSTRY COMPANY, LIMITED | 2004-06-10 | — | — | US | disclosed |
| EP-1426047-A1 | Anti-tumour pharmaceutical composition comprising N-vanillyl fatty acid amide | Kureha Chemical Industry Company, Limited (JP) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119423-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN | TRPV1, SCN3A, OPRK1 | TAAR1 2891/4885TSHR 4736/4885MAPK1 2473/4885 |
| US-20040110844-A1 | Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide | ELOVL1, TRPV1, ELOVL5 | TAAR1 2947/4885TSHR 4725/4885MAPK1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.